TORONTO, July 26, 2021 /CNW/ -Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (FSE: 8TV), a health-tech company focused on building a generation of better brains, is pleased to announce approval from Health Canada to sell Nuro Drive ("Drive") and Nuro Restore ("Restore"), its proprietary nutraceutical products, in the Canadian market. Nurosene's products are currently available for sale in the United States via the Company's e-commerce website at shop.nurosene.com.
Nurosene previously submitted requests to Health Canada earlier this year for Licensed Natural Product Numbers and have received approvals for both Drive and Restore. In order to sell products via both retail channels and direct to consumers in the Canadian market, a Licensed Natural Product Number is required. Importantly, Licensed Natural Products have been assessed by Health Canada and classified as high quality, safe, and effective under their recommended conditions of use.
"Entering the Canadian market represents a significant milestone for Nurosene, providing multiple opportunities for enhanced brand visibility to help our consumers build better brain health, while simultaneously growing revenue due to our expanded footprint," said Co-Founder Daniel Gallucci. "We are thrilled to offer our Drive and Restore nutraceuticals in my home country and our continued expansion in the North American market remains a critical component of our growth strategy," concluded Mr. Gallucci.
Nurosene's supplements are unique, research-backed and designed to help tackle the complexities that life hands you, further supporting consumers' optimal performance levels. Both Drive and Restore products were designed by Co-Founder Daniel Gallucci, who has spent the last few decades validating them in clinics.
Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI and machine learning. With our team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments. The company is based in Toronto, Ontario.
For more information, visit www.nurosene.com
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect," "likely," "may," "will," "should," "intend," "anticipate," "potential," "proposed", "estimate," and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may," "would," or "will," happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, activities of the Company's Nutraceutical supplement sales and offerings.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Nurosene Health Inc.
For further information: KCSA Strategic Communications | Valter Pinto, Managing Director | Valter@KCSA.com | (212) 896-1254; Blake Sing, Chief Financial Officer | email@example.com | (416) 859-8838
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDAR.com for important risk disclosures. It’s your money and your responsibility.